Citeline and Norstella Complete Merger to Form a $5 Billion Global Pharmaceutical Technology Company
PR98561
YARDLEY, Pa., Nov. 1, 2022 /PRNewswire=KYODO JBN/ --
-- With more than 1,600 employees across the globe, the new organization is now
one of the world's largest pharma intelligence solutions providers on the market
Norstella(
), a global leader with end-to-end solutions that smooth access to life-saving
therapies for patients, has announced the completion of its merger with
Citeline(
) (formerly Pharma Intelligence), a leader in the clinical trial intelligence
space.
At deal close, the $5 billion global company is now one of the world's largest
pharma intelligence solutions providers on the market, with more than 1,600
employees across the five brands that make up Norstella: Evaluate(
), MMIT(
), Panalgo(
https://c212.net/c/link/?t=0&l=en&o=3692380-1&h=1773826237&u=https%3A%2F%2Fpanalgo.com%2F&a=Panalgo
), The Dedham Group(
), and now Citeline(
).
This merger will allow Norstella to prioritize rapid innovation to help guide
life sciences companies through the entire drug development process so patients
can get access to therapies quicker.
"We believe that patient access starts with identifying unmet needs and doesn't
end until a patient has a therapy in hand," said Mike Gallup, CEO of Norstella(
). "As the industry moves toward highly targeted therapies focused on smaller
patient populations, our clients need solutions that provide actionable answers
to critical business questions to help bring drugs to market quicker—ultimately
helping patients receive treatment sooner."
From the clinical discovery process through commercialization, pharma
manufacturers are overwhelmed with data and inundated with questions around
applying real-world data, understanding the burden of disease, communicating
the clinical efficacy of a drug, revealing an unanticipated positive clinical
outcome or quantifying the consequence of a delayed therapy to market.
As a combined organization, Norstella's solutions will empower pharma
stakeholders to identify unmet clinical needs early, construct clinical trials
with informed endpoints that support downstream reimbursement decisions, and
precisely identify eligible patients for clinical trials. A powerful example of
this is Panalgo's Instant Health Data (IHD) platform(
), which can ingest Citeline's clinical trial and real-world data, MMIT's
policy, restriction and patient lab data, and The Dedham Group's clinical
pathway data and real-world evidence—all of which can be harnessed to quickly
answer key questions related to the patient journey, payer reimbursement, and
the safety and efficacy of therapeutics.
"This union is an opportunity for both Citeline and Norstella to advance their
shared mission of making therapies available to the patients who need them,"
said Jay Nadler, Executive Chair of Norstella and Ramsey Hashem, CEO of
Citeline. "We feel an urgency to make an impact, and we believe that we can
bring innovation that will change patients' lives."
Added Gallup, "A key philosophy at Norstella is to innovate in partnership with
our clients; we will continue to ask our clients where there is a gap and how
we can close it. Together, we're aiming to create a healthcare marketplace
that's more innovative and accessible for all."
About Norstella
At Norstella, our mission is simple: to help patients gain access to
life-saving therapies. Norstella consists of several prominent
organizations—Citeline, Evaluate, MMIT, Panalgo and The Dedham Group—that have
united to offer a full range of pharmaceutical consultancy services and
solutions. As one organization, Norstella provides life sciences clients with
the right tools and expertise to navigate complexities at each step of the drug
development life cycle, from pipeline to patient. For more information, visit
Norstella(
) and follow on LinkedIn(
).
About Citeline
Citeline (formerly Pharma Intelligence) powers a full suite of complementary
business intelligence offerings to meet the evolving needs of life science
professionals to accelerate the connection of treatments to patients and
patients to treatments. These patient-focused solutions and services deliver
and analyze data used to drive clinical, commercial, and regulatory
related-decisions and create real-world opportunities for growth.
Our global teams of analysts, journalists and consultants keep their fingers on
the pulse of the pharmaceutical, biomedical and medtech industries, covering it
all with expert insights: key diseases, clinical trials, drug R&D and
approvals, market forecasts and more. For more information on one of the
world's most trusted life science partners, visit Citeline(
).
Media Contacts
Norstella
Melody Udell | Director, Communications
+1 312-618-5968 | melody.udell@norstella.com
Citeline
Blair Dawson | Vice President, Communications and Employee Engagement
+1 919-413-4616 | blair.dawson@informa.com
SOURCE: Norstella
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
